ginkgolide B

01/31/2010 - "In conclusion, Ginkgolide B could pass through BBB, especially after ischemia-reperfusion injury of brain, and might be therapeutically effective for ischemia/reperfusion injury of human brain."
01/31/2010 - "Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia-reperfusion injury."
04/01/2010 - "Ginkgolide B has protective effects on cerebral injury by inhibiting the inflammation induced by ischemia/reperfusion injury."
01/01/2020 - "Ginkgolide B Ameliorates Myocardial Ischemia Reperfusion Injury in Rats via Inhibiting Endoplasmic Reticulum Stress [Retraction]."
01/01/2019 - "Ginkgolide B ameliorates myocardial ischemia reperfusion injury in rats via inhibiting endoplasmic reticulum stress."

02/01/2011 - "Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study."
02/01/2011 - "Ginkgolide B, a herbal constituent extract from Ginkgo biloba tree leaves, was considered as a promising pharmacological aid for the treatment of migraine in adult patients because of its modulation of the glutamatergic transmission in the CNS and on antiplatelet activating factor (PAF). "
06/01/2010 - "Finally, ginkgolide B has proved significantly effective in controlling migraine with aura and pediatric migraine in uncontrolled studies that need a confirmation."
05/01/2013 - "The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial."
06/01/2010 - "These preliminary data show that Ginkgolide B seems to be effective as preventive treatment in reducing migraine attack frequency and in attenuating the use of symptomatic medication in our small series of children with primary headache."

05/01/2009 - "Efficacy of Ginkgolide B in the prophylaxis of migraine with aura."
05/01/2009 - "In a multicentric, open, preliminary trial, we evaluated the use of ginkgolide B, a herbal constituent extract from Ginkgo biloba tree leaves, in the prophylactic treatment of migraine with aura (MA). "
06/01/2010 - "Finally, ginkgolide B has proved significantly effective in controlling migraine with aura and pediatric migraine in uncontrolled studies that need a confirmation."
05/01/2013 - "In this open trial we evaluated the possible efficacy of Ginkgolide B in the treatment of acute aura in a group of patients suffering from migraine with aura, considering in particular the effect of the treatment on aura duration. "
01/01/2015 - "Recent studies show anxiolytic properties of ginkgolide A, migraine with aura treatment by ginkgolide B, a reduction in ischemia-induced glutamate excitotoxicity by bilobalide, and an alternative antihypertensive property of quercetin, among others. "

01/01/2018 - "Here, we studied whether Ginkgolide B (GB), an effective anti-inflammatory monomer, improved MI/RI via suppression of inflammation. "
01/01/2022 - "Ginkgolide B (GB) is a potential anti-inflammatory compound that controls neuro-inflammation. "
05/01/2021 - "XQ-1H is a new compound derived from the structure modification of ginkgolide B, which exerts anti-inflammation and neuroprotection against cerebral ischemic injury during the acute or subacute phase. "
01/01/2019 - "Ginkgolide B (GB), a derivative of Ginkgo biloba leaves, has numerous pharmacological effects, including anticancer and anti-inflammation activities. "
04/01/2005 - "To investigate the inhibitory effect of ginkgolide B on angiogenesis in chronic inflammation and the possible mechanisms. "

11/01/1994 - "BN 52021 Sepsis Study Group."
12/01/1998 - "BN 52021 Sepsis Investigator Group."
01/01/1993 - "Preliminary results with BN 52021 indicate that it is efficacious and significantly reduces mortality associated with Gram-negative sepsis. "
12/01/1998 - "A 4-day administration of the studied PAFra (BN 52021) failed to demonstrate a statistically significant reduction in the mortality rate of patients with severe sepsis suspected to be related to Gram-negative bacterial infection. "
11/01/1994 - "The studied platelet-activating factor receptor antagonist (BN 52021) seems to be a safe and promising treatment for patients with severe Gram-negative sepsis."